Dopaminergic therapy selectively amplifies hallucination susceptibility in patients with Parkinson’s disease with cortico-striatal hyperconnectivity
medRxiv September 3, 2026 Fosco Bernasconi, Sara Stampacchia, Lucas Burget et al. preprint
Dopamine replacement therapy (DRT) alleviates motor symptoms in Parkinson’s disease (PD) but can trigger hallucinations in a subset of patients, yet the neural basis of this selective vulnerability is unknown. Hallucinations are among the most disabling non-motor symptoms of PD, linked to social isolation, dementia and institutionalization. Using a validated robotic paradigm to induce and...